HIT Consultant November 30, 2022
What You Should Know:
– Rgenta Therapeutics Inc. raises a $52M Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos Capital.
– Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets.
Targeting the “Undruggables”
Only a quarter of the proteins implicated in human diseases are currently druggable by traditional approaches for developing small-molecules compounds. Thus, new approaches directly targeting messenger RNAs of disease genes open up unprecedented opportunities for drug development. Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. The company’s proprietary platform mines the massive genomics data to identify...
Today's Sponsors
Today's Sponsor